Literature DB >> 32730114

The FGF/FGFR system in the physiopathology of the prostate gland.

Arianna Giacomini1, Elisabetta Grillo1, Sara Rezzola1, Domenico Ribatti1, Marco Rusnati1, Roberto Ronca1, Marco Presta1.   

Abstract

Fibroblast growth factors (FGFs) are a family of proteins possessing paracrine, autocrine, or endocrine functions in a variety of biological processes, including embryonic development, angiogenesis, tissue homeostasis, wound repair, and cancer. Canonical FGFs bind and activate tyrosine kinase FGF receptors (FGFRs), triggering intracellular signaling cascades that mediate their biological activity. Experimental evidence indicates that FGFs play a complex role in the physiopathology of the prostate gland that ranges from essential functions during embryonic development to modulation of neoplastic transformation. The use of ligand- and receptor-deleted mouse models has highlighted the requirement for FGF signaling in the normal development of the prostate gland. In adult prostate, the maintenance of a functional FGF/FGFR signaling axis is critical for organ homeostasis and function, as its disruption leads to prostate hyperplasia and may contribute to cancer progression and metastatic dissemination. Dissection of the molecular landscape modulated by the FGF family will facilitate ongoing translational efforts directed toward prostate cancer therapy.

Entities:  

Keywords:  FGF; cancer; development; nonmalignant pathology; physiology; prostate

Mesh:

Substances:

Year:  2020        PMID: 32730114     DOI: 10.1152/physrev.00005.2020

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  8 in total

Review 1.  The lymphatic vasculature: An active and dynamic player in cancer progression.

Authors:  Sara Rezzola; Elena C Sigmund; Cornelia Halin; Roberto Ronca
Journal:  Med Res Rev       Date:  2021-09-05       Impact factor: 12.388

Review 2.  The Extracellular Matrix Stiffening: A Trigger of Prostate Cancer Progression and Castration Resistance?

Authors:  Carole Luthold; Tarek Hallal; David P Labbé; François Bordeleau
Journal:  Cancers (Basel)       Date:  2022-06-11       Impact factor: 6.575

Review 3.  Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives.

Authors:  Alessandra Loda; Marta Turati; Francesco Semeraro; Sara Rezzola; Roberto Ronca
Journal:  Int J Mol Sci       Date:  2022-03-30       Impact factor: 5.923

Review 4.  Angiogenesis as Therapeutic Target in Metastatic Prostate Cancer - Narrowing the Gap Between Bench and Bedside.

Authors:  Antonio Giovanni Solimando; Charis Kalogirou; Markus Krebs
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

5.  Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing.

Authors:  Sujin Hyung; Boram Han; Jaeyun Jung; Seung Tae Kim; Jung Yong Hong; Se Hoon Park; Dae Young Zang; Joon Oh Park; Young Suk Park; Kyoung-Mee Kim; Won Ki Kang; Jeeyun Lee
Journal:  J Oncol       Date:  2022-03-18       Impact factor: 4.375

6.  Phenotypic spectrum of FGF10-related disorders: a systematic review.

Authors:  Katarzyna Bzdega; Justyna A Karolak
Journal:  PeerJ       Date:  2022-09-14       Impact factor: 3.061

7.  Reciprocal interaction between vascular niche and sweat gland promotes sweat gland regeneration.

Authors:  Xingyu Yuan; Xianlan Duan; Zhao Li; Bin Yao; Wei Song; Yuzhen Wang; Yi Kong; Shijun Zhu; Fanliang Zhang; Liting Liang; Mengde Zhang; Chao Zhang; Deling Kong; Meifeng Zhu; Sha Huang; Xiaobing Fu
Journal:  Bioact Mater       Date:  2022-09-14

8.  Increased Expression and Altered Cellular Localization of Fibroblast Growth Factor Receptor-Like 1 (FGFRL1) Are Associated with Prostate Cancer Progression.

Authors:  Lan Yu; Mervi Toriseva; Syeda Afshan; Mario Cangiano; Vidal Fey; Andrew Erickson; Heikki Seikkula; Kalle Alanen; Pekka Taimen; Otto Ettala; Martti Nurmi; Peter J Boström; Markku Kallajoki; Johanna Tuomela; Tuomas Mirtti; Inès J Beumer; Matthias Nees; Pirkko Härkönen
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.